Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 2
1979 1
1980 3
1982 1
1986 14
1987 11
1988 2
1989 4
1990 9
1991 10
1992 12
1993 9
1994 4
1995 28
1996 11
1997 11
1998 11
1999 10
2000 9
2001 12
2002 7
2003 7
2004 7
2005 6
2006 2
2007 6
2008 5
2009 6
2010 4
2011 3
2012 7
2013 6
2014 3
2015 1
2016 2
2017 3
2018 1
2019 3
2020 2
2021 2
2022 2
2023 4
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

253 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetics of isepamicin.
Barr WH, Colucci R, Radwanski E, Zampaglione N, Cutler D, Lin CC, Elliott M, Affrime MB. Barr WH, et al. J Chemother. 1995 Jun;7 Suppl 2:53-61. J Chemother. 1995. PMID: 8622111 Review.
Isepamicin is a new aminoglycoside that has activity against many bacteria resistant to other aminoglycosides. ...The gamma-phase represents less than 3% of the total AUC and does not change with age. Isepamicin readily distributes to extracellular fluid and pulmona
Isepamicin is a new aminoglycoside that has activity against many bacteria resistant to other aminoglycosides. ...The gamma-phase rep
Clinical pharmacokinetics and pharmacodynamics of isepamicin.
Tod M, Padoin C, Petitjean O. Tod M, et al. Clin Pharmacokinet. 2000 Mar;38(3):205-23. doi: 10.2165/00003088-200038030-00002. Clin Pharmacokinet. 2000. PMID: 10749517 Review.
The clearance of isepamicin is reduced in neonates, and 7.5 mg/kg once daily is recommended in children <16 days old. ...Isepamicin can induce nephro-, vestibulo- and oto-toxicity. However, animal and clinical studies show that isepamicin is one of the les …
The clearance of isepamicin is reduced in neonates, and 7.5 mg/kg once daily is recommended in children <16 days old. ...Isepam
Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity.
Jones RN. Jones RN. J Chemother. 1995 Jun;7 Suppl 2:7-16. J Chemother. 1995. PMID: 8622113 Review.
The spectrum of isepamicin is most similar to that of amikacin, another aminoglycoside with high enzyme stability. Reviews of isepamicin activity demonstrate MIC90s ranging from 1.1 to 8.5 mg/L for members of the Enterobacteriaceae, slightly more potent than amikaci …
The spectrum of isepamicin is most similar to that of amikacin, another aminoglycoside with high enzyme stability. Reviews of isep
Susceptibility of Gram-negative bacteria to isepamicin: a systematic review.
Falagas ME, Karageorgopoulos DE, Georgantzi GG, Sun C, Wang R, Rafailidis PI. Falagas ME, et al. Expert Rev Anti Infect Ther. 2012 Feb;10(2):207-18. doi: 10.1586/eri.11.170. Expert Rev Anti Infect Ther. 2012. PMID: 22339194 Review.
In the clinical studies, isepamicin was as active as amikacin for the treatment of 55 children with urinary tract infections. In conclusion, isepamicin might be active in vitro against Gram-negative bacteria with resistance to amikacin and other aminoglycosides....
In the clinical studies, isepamicin was as active as amikacin for the treatment of 55 children with urinary tract infections. In conc …
In-vitro Activity of Isepamicin against Gram-negative Bacteria in Comparison to Other Aminoglycosides Routinely used at a Teaching Hospital in Northern India.
Siddiqui T, Kar M, Dubey A, Patel SS, Sahu C. Siddiqui T, et al. J Lab Physicians. 2023 Mar 22;15(3):419-424. doi: 10.1055/s-0043-1761928. eCollection 2023 Sep. J Lab Physicians. 2023. PMID: 37564217 Free PMC article.
Among the non-inducible Enterobacteriaceae , Escherichia coli was least susceptible to amikacin (8/27, 29.63%) and most susceptible to isepamicin (18/27, 66.67%). Klebsiella pneumoniae followed the same pattern of susceptibility as E. coli and was least susceptible to Amik …
Among the non-inducible Enterobacteriaceae , Escherichia coli was least susceptible to amikacin (8/27, 29.63%) and most susceptible to is
Investigation of isepamicin in vitro efficiency in Gram negative bacteria efficacy of isepamicin.
Yeliz TC, Ali HB, Sarah AF, Sreylis N, Kubra HU, Asuman B. Yeliz TC, et al. Indian J Med Microbiol. 2021 Jan;39(1):59-62. doi: 10.1016/j.ijmmb.2020.09.003. Epub 2020 Nov 2. Indian J Med Microbiol. 2021. PMID: 33610258
CONTEXT: Isepamicin is a new semisynthetic aminoglycoside derived from gentamicin B and it is effective against Gram negative bacteria. ...But amikacin was prior to isepamicin P. aeruginosa isolates. Isepamicin could be a therapeutic option for the infections …
CONTEXT: Isepamicin is a new semisynthetic aminoglycoside derived from gentamicin B and it is effective against Gram negative bacteri …
Isepamicin versus amikacin for the treatment of acute pyelonephritis in children.
Kafetzis DA, Maltezou HC, Mavrikou M, Siafas C, Paraskakis I, Delis D, Bartsokas C. Kafetzis DA, et al. Int J Antimicrob Agents. 2000 Feb;14(1):51-5. doi: 10.1016/s0924-8579(99)00138-7. Int J Antimicrob Agents. 2000. PMID: 10717501 Clinical Trial.
In this study we compared the efficacy and safety of isepamicin versus amikacin at a dose of 7.5 mg/kg i.v. q12h for 10-14 days in children with pyelonephritis. Sixteen children were enrolled in the study; ten received isepamicin and six amikacin. Urine cultures gre …
In this study we compared the efficacy and safety of isepamicin versus amikacin at a dose of 7.5 mg/kg i.v. q12h for 10-14 days in ch …
Once daily isepamicin treatment in complicated urinary tract infections.
Lee SS, Liu YC, Wann SR, Lin WR, Tsai TH, Lin HH, Chen YS, Yen MY. Lee SS, et al. J Microbiol Immunol Infect. 1999 Jun;32(2):105-10. J Microbiol Immunol Infect. 1999. PMID: 11561574 Clinical Trial.
Seven (3 isepamicin and 4 amikacin) adverse events were considered probably or possibly related to the study drug, which included eosinophilia (2 isepamicin), liver function impairment (1 isepamicin, 2 amikacin), renal function impairment (1 amikacin) and flu …
Seven (3 isepamicin and 4 amikacin) adverse events were considered probably or possibly related to the study drug, which included eos …
Isepamicin disposition in subjects with various degrees of renal function.
Halstenson CE, Kelloway JS, Affrime MB, Lin CC, Teal MA, Shapiro BE, Awni WM. Halstenson CE, et al. Antimicrob Agents Chemother. 1991 Nov;35(11):2382-7. doi: 10.1128/AAC.35.11.2382. Antimicrob Agents Chemother. 1991. PMID: 1804011 Free PMC article.
Nonrenal clearance of isepamicin did not differ between groups. Hemodialysis augmented the CLP of isepamicin by approximately 25-fold. The amount of isepamicin recovered in the dialysate was 60.6 +/- 15.8% of the dose administered. The maximal rebound of the …
Nonrenal clearance of isepamicin did not differ between groups. Hemodialysis augmented the CLP of isepamicin by approximately …
Rabbits treated with chronic isepamicin are resistant to mivacurium and rocuronium.
Kim KS, Shim JC, Jun JH, Lee KH, Chung CW. Kim KS, et al. Anesth Analg. 1999 Mar;88(3):654-8. doi: 10.1097/00000539-199903000-00034. Anesth Analg. 1999. PMID: 10072022
Chronic isepamicin therapy is associated with a rightward shift of the mivacurium and rocuronium dose-response curves. ...The results of this study show that mivacurium and rocuronium have both a decreased effect and a shorter duration of action in rabbits when used during …
Chronic isepamicin therapy is associated with a rightward shift of the mivacurium and rocuronium dose-response curves. ...The results …
253 results